Epithelial cell adhesion molecule is a prognosis marker for intrahepatic cholangiocarcinoma

Journal of Surgical Research

Volumn 192, Issue 1, 2014, Pages 117-123

  Sulpice, Laurent ^a,b   Rayar, Michel ^b   Turlin, Bruno ^a,b,c   Boucher, Eveline ^a,b,d   Bellaud, Pascale ^a,b   Desille, Mireille ^a,b   Meunier, Bernard ^b   Clément, Bruno ^a,b   Boudjema, Karim ^a,b   Coulouarn, Cédric ^a,b  

^a Univ Rennes   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d Ctr Reg de Lutte Contre le Cancer   (France)

Author keywords

Biomarkers; Intrahepatic cholangiocarcinoma; Prognosis

Indexed keywords

BIOLOGICAL MARKER; CD133 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; CD44 PROTEIN, HUMAN; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; TRANSCRIPTOME; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; BILE DUCT CARCINOMA; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STEM CELL; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; EMBRYONIC STEM CELL; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; TISSUE MICROARRAY; TUMOR VOLUME; UPREGULATION; AGED; BILE DUCT NEOPLASMS; CELL ADHESION; CHOLANGIOCARCINOMA; CYTOLOGY; EPITHELIUM CELL; FOLLOW UP; GENETICS; INTRAHEPATIC BILE DUCT; METABOLISM; MIDDLE AGED; MORTALITY; PHYSIOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR RECURRENCE;

AGED; ANTIGENS, CD; ANTIGENS, CD44; ANTIGENS, NEOPLASM; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL ADHESION; CELL ADHESION MOLECULES; CHOLANGIOCARCINOMA; EPITHELIAL CELLS; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84918501018     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2014.05.017     Document Type: Article

References (28)

1. Taylor-Robinson SD, Toledano MB, Arora S, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001;48:816.
2. Ercolani G, Vetrone G, Grazi GL, et al. Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival. Ann Surg 2010;252:107.
3. Maithel SK, Gamblin TC, Kamel I, et al. Multidisciplinary approaches to intrahepatic cholangiocarcinoma. Cancer; 2013.
4. Sulpice L, Rayar M, Boucher E, et al. Treatment of recurrent intrahepatic cholangiocarcinoma. Br J Surg 2012;99:1711.
5. Komuta M, Spee B, Vander BS, et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 2008;47:1544.
6. Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013; 144:829.
7. Sulpice L, Rayar M, Desille M, et al. Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma. Hepatology 2013;58:1992.
8. de Boer CJ, van Krieken JH, Janssen-van Rhijn CM, Litvinov SV. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol 1999;188:201.
9. Ma YC, Yang JY, Yan LN. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis. Eur J Gastroenterol Hepatol 2013; 25:1007.
10. Coulouarn C, Corlu A, Glaise D, et al. Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res 2012;72:2533.
11. Ben-Porath I, Thomson MW, Carey VJ, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008;40: 499.
12. Iwahashi S, Utsunomiya T, Shimada M, et al. High expression of cancer stem cell markers in cholangiolocellular carcinoma. Surg Today 2013;43:654.
13. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105.
14. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 2006;25: 3818.
15. Woo HG, Lee JH, Yoon JH, et al. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res 2010;70:3034.
16. Roskams TA, Theise ND, Balabaud C, et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology 2004;39: 1739.
17. Cai X, Zhai J, Kaplan DE, et al. Background progenitor activation is associated with recurrence after hepatectomy of combined hepatocellular-cholangiocarcinoma. Hepatology 2012;56:1804.
18. Coulouarn C, Cavard C, Rubbia-Brandt L, et al. Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFbeta signaling pathways. Carcinogenesis 2012;33:1791.
19. Li L, Xie T. Stem cell niche: structure and function. Annu Rev Cell Dev Biol 2005;21:605.
20. Dong HH, Xiang S, Liang HF, et al. The niche of hepatic cancer stem cell and cancer recurrence. Med Hypotheses 2013;80:666.
21. Kokuryo T, Yokoyama Y, Nagino M. Recent advances in cancer stem cell research for cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2012;19:606.
22. Shimada M, Sugimoto K, Iwahashi S, et al. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gastroenterol 2010;45:896.
23. Wang M, Xiao J, Jiang J, Qin R. CD133 and ALDH may be the molecular markers of cholangiocarcinoma stem cells. Int J Cancer 2011;128:1996.
24. Wang M, Xiao J, Shen M, et al. Isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell-like properties. Int J Cancer 2011;128:72.
25. Yamashita T, Ji J, Budhu A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009; 136:1012.
26. Oberneder R, Weckermann D, Ebner B, et al. A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. Eur J Cancer 2006;42:2530.
27. Moldenhauer G, Salnikov AV, Luttgau S, et al. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J Natl Cancer Inst 2012;104:622.
28. Schmidt M,Ruttinger D, Sebastian M, et al. Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patientswithEpCAM-positive relapsedor refractoryadvancedstage breast cancer. Ann Oncol 2012;23:2306.